Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma.
Buhl R, Solèr M, Matz J, Townley R, O'Brien J, Noga O, Champain K, Fox H, Thirlwell J, Della Cioppa G.
Buhl R, et al. Among authors: noga o, o brien j.
Eur Respir J. 2002 Jul;20(1):73-8. doi: 10.1183/09031936.02.00278102.
Eur Respir J. 2002.
PMID: 12166585
Free article.
Clinical Trial.